How to Analyse Pharmaceutical Companies

To analyse a pharmaceutical company, judge three things the ordinary metrics miss: how exposed its profits are to patent expiries, whether its R&D spending earns a real return, and how deep its pipeline is. A great pharma business replaces expiring revenue faster than it loses it, and funds that from its own cash flow.

Pharma looks like a quality sector from a distance: high margins, repeat demand, products people cannot do without. Up close it is more demanding, because much of today’s profit rests on patents that will expire on a known date.

Where this fits: this is a sector-specific adaptation of the Five Criteria framework. It builds on how to spot an economic moat and return on invested capital, applied to drug companies.

Why Pharma Needs Its Own Playbook

Most businesses decay slowly. A pharmaceutical company’s best products decay on a schedule. A patent grants a period of exclusivity, and when it ends, generic or biosimilar rivals enter and the price of that drug can fall sharply within a year or two.

This single feature changes how you read every other number. A pharma company can show rising revenue, fat margins and a cheap-looking multiple while sitting on a cliff that will remove a quarter of its profit in three years.

So the ordinary quality checks are necessary but not sufficient. You have to layer three sector-specific questions on top: patent exposure, R&D productivity, and pipeline depth.

The Patent Cliff: The Risk That Defines the Sector

Start every pharma analysis with one exercise. List the company’s largest products, find the approximate year each loses exclusivity, and work out what share of revenue and profit is exposed over the next five to ten years.

How to read patent exposure

Companies disclose their major patent expiries in annual reports and regulatory filings, because they are material risks. Pull them together into a simple table.

Question	Why it matters
What share of revenue comes from the top three drugs?	Concentration magnifies cliff risk
When does each lose exclusivity?	Tells you the timing of the hit
Is it a small-molecule drug or a biologic?	Biologics face biosimilars, which erode more slowly than generics
Is there a next-generation version ready?	Reformulations and follow-ons can soften the fall

A company earning most of its profit from one drug with three years of patent life left is a very different proposition from one whose largest product is 8% of sales.

Generics versus biosimilars

The erosion is not uniform. Traditional small-molecule drugs face cheap chemical copies, and the price collapse can be severe and fast once several generics launch.

Biologics are large, complex molecules that are harder to copy exactly, so their rivals are “biosimilars” rather than identical generics. Erosion tends to be slower and less complete, which makes a biologics-heavy portfolio somewhat more durable, all else equal.

R&D Productivity: Is the Spending Earning a Return?

Pharma companies spend heavily on research. The mistake is to treat that spending as automatically virtuous. R&D is capital allocation, and the only question that matters is the one you would ask of any investment: what return does it earn?

Output, not input

A company can boast a large R&D budget while its approval rate falls and its new launches underwhelm. That is capital destruction dressed up as ambition. Judge the output:

• How many meaningful new drugs has it brought to market in the last five to ten years?
• Are those launches growing into real revenue, or quietly disappointing?
• Is the company’s own pipeline replacing what the patent cliff removes?

This is the same discipline we apply in the hierarchy of capital allocation. Money spent on research that does not produce approved, profitable drugs is money lost, however noble the intention.

The role of acquisitions

Large pharma companies frequently buy smaller biotechs to fill gaps in their pipeline. This can be sensible, but it is also where a lot of shareholder value is quietly handed over. Watch for a pattern of expensive deals timed to paper over a thinning internal pipeline. A company that must keep buying growth is telling you its own research is not productive enough.

Pipeline Depth: Are Future Profits Already in View?

The pipeline is the set of drug candidates working through development. It is the reason you can pay more than the value of today’s products — but only if it is deep and diversified.

Why you cannot value a pipeline precisely

Most drug candidates fail. They fail in trials, they fail at the regulator, they fail commercially after launch. Anyone presenting you a precise valuation of an early-stage pipeline is selling false confidence.

The honest approach is to anchor your valuation on the approved, on-market portfolio, then treat the pipeline as optionality that needs a wide margin of safety. Diversification across several candidates, disease areas and development stages is worth far more than a single exciting late-stage bet, because it does not depend on one coin landing the right way up.

A hypothetical comparison

The following is a hypothetical example for illustration only.

Imagine two companies, Pharma A and Pharma B. Both earn similar profit today.

• Pharma A gets 60% of profit from one drug losing exclusivity in three years, with a thin pipeline behind it.
• Pharma B has no drug above 15% of sales, a spread of products across several therapy areas, and a diversified mid- and late-stage pipeline.

On a simple earnings multiple, Pharma A might look cheaper. But Pharma B is the higher-quality business, because its profit is durable and Pharma A’s is partly borrowed from a future it is about to lose. Price without context is misleading here more than almost anywhere else.

Adapting the Five Criteria to Pharma

Here is how the house framework translates to drug companies.

Criterion 1: A great business (high ROIC)

ROIC still works, and the best pharma companies earn high returns on capital thanks to pricing power during exclusivity. But look at the trend and the five-year average, because a single blockbuster can flatter one year. Cross-reference with ROIC as the gold standard.

Criterion 2: A durable moat

The moat is not brand in the consumer sense. It is patents, regulatory expertise, manufacturing scale (especially for biologics), and distribution relationships. The key word is durable: patents expire, so the real moat is the organisation’s repeatable ability to discover and launch new drugs. See how to spot a moat.

Criterion 3: Aligned management

Capital allocation is everything in pharma. Does management buy back stock at sensible prices, make disciplined acquisitions, and avoid vanity R&D? Our guide to identifying great management applies directly.

Criterion 4: A sound balance sheet

Big pharma is usually cash-generative and can carry moderate debt comfortably. Keep the house defaults in mind — net debt to EBITDA around 2x or less and interest coverage comfortably above 5x — but be stricter with a company facing a near-term cliff, because leverage plus falling revenue is a dangerous mix. Revisit interest coverage if needed.

Criterion 5: A reasonable price

This is where pharma demands the most adjustment. A low multiple often reflects a coming patent cliff that the market has correctly priced. Build your valuation on durable, replaceable earnings, discount for the cliff explicitly, and insist on a margin of safety. A discounted cash flow that steps revenue down for known expiries is more honest than a flat multiple.

A Simple Pharma Checklist

Before you go further on any drug company, run through these:

1. What percentage of profit faces patent expiry in the next five years?
2. Is the pipeline deep and diversified enough to replace it?
3. Has R&D produced approved, growing drugs over the last decade?
4. Is management buying growth to hide a thinning internal pipeline?
5. Does the balance sheet leave room if a key trial or launch disappoints?
6. Does the price already reflect the known cliffs, with a margin of safety left over?

If the answers line up, you may have a durable compounder. If the business leans on one ageing blockbuster with little behind it, a cheap multiple is a warning, not an invitation.

Frequently Asked Questions

What is a patent cliff? A patent cliff is the sharp drop in a drug’s revenue once its patent expires and generic or biosimilar competitors enter. Prices can fall by the majority within a year or two, so a company reliant on one or two ageing blockbusters can lose a large share of profit almost overnight.

Is high R&D spending a good sign in pharma? Not on its own. R&D is an investment, and like any investment it only creates value if it earns a decent return. A company spending heavily while its approval rate and pipeline quality decline is destroying capital, not building a moat. Look at output, not just input.

How do I value a drug pipeline I cannot see the results of? You cannot value it precisely, and you should not pretend to. Treat the approved, on-market portfolio as the valuation base, then ask whether the pipeline is deep and diversified enough to replace expiring revenue. Build a margin of safety for the drugs that will fail, because most do.

Do the Five Criteria work for pharma stocks? Yes, with sector-specific adjustments. ROIC and cash generation still matter; the moat is patents, scale and regulatory know-how rather than brand; and the reasonable-price test must explicitly account for patent expiries in the next five to ten years.

Your Next Step

Take one pharma company you follow and build the patent-exposure table above: top drugs, expiry years, share of profit at risk. Then sanity-check the price with our DCF intrinsic value calculator and score the business against the Five Criteria framework. For a deeper toolkit on valuing the pipeline, surviving patent cliffs and judging R&D returns, see The Pharma Compass and the other premium sector playbooks.

---

About the author: Cameron Hayes is a senior investor relations and finance professional who has worked in IR at Nasdaq Copenhagen-listed companies including Nilfisk and Maersk Drilling. He holds an MSc from Copenhagen Business School and a BCom from the University of Ottawa, and founded Gingernomics to teach individual investors the Five Criteria framework. More about Gingernomics.

The content on Gingernomics is for educational and informational purposes only and does not constitute financial advice. Always do your own research and consult a licensed financial advisor before making any investment decisions. Past performance is not indicative of future results.